REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS

Details for Australian Patent Application No. 2002306943 (hide)

Owner LEXIGEN PHARMACEUTICALS CORP.

Inventors GILLIES, Stephen, D.

Pub. Number AU-A-2002306943

PCT Number PCT/US02/09650

PCT Pub. Number WO2002/079415

Priority 60/280,625 30.03.01 US

Filing date 29 March 2002

Wipo publication date 15 October 2002

Event Publications

19 December 2002 Complete Application Filed

  Priority application(s): 60/280,625 30.03.01 US

3 April 2003 Application Open to Public Inspection

  Published as AU-A-2002306943

17 July 2003 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  Application withdrawn under section 141(3)/See Reg. 8.3(2). Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002306944-SPIDER SILK PROTEIN ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHOD OF USE THEREOF

2002306942-TRANSGENIC MICE CONTAINING CLCN7 CHLORIDE CHANNEL GENE DISRUPTIONS